Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.
2.

A comparison of peginterferon α-2a and α-2b for treatment-naive patients with chronic hepatitis C virus: A meta-analysis of randomized trials.

Zhao S, Liu E, Chen P, Cheng D, Lu S, Yu Q, Wang Y, Wei K, Yang P.

Clin Ther. 2010 Aug;32(9):1565-77. doi: 10.1016/j.clinthera.2010.08.009. Review.

PMID:
20974315
3.

Comparison of peginterferon pharmacokinetic and pharmacodynamic profiles.

Bruno R, Sacchi P, Cima S, Maiocchi L, Novati S, Filice G, Fagiuoli S.

J Viral Hepat. 2012 Jan;19 Suppl 1:33-6. doi: 10.1111/j.1365-2893.2011.01519.x. Review.

PMID:
22233411
4.

Peginterferon alpha-2a versus peginterferon alpha-2b for chronic hepatitis C.

Hauser G, Awad T, Thorlund K, Štimac D, Mabrouk M, Gluud C.

Cochrane Database Syst Rev. 2014 Feb 28;(2):CD005642. doi: 10.1002/14651858.CD005642.pub3. Review.

PMID:
24585451
5.
6.

Peginterferon plus ribavirin versus interferon plus ribavirin for chronic hepatitis C.

Hauser G, Awad T, Brok J, Thorlund K, Štimac D, Mabrouk M, Gluud C, Gluud LL.

Cochrane Database Syst Rev. 2014 Feb 28;(2):CD005441. Review.

PMID:
24585509
7.

Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.

Shepherd J, Brodin H, Cave C, Waugh N, Price A, Gabbay J.

Health Technol Assess. 2004 Oct;8(39):iii-iv, 1-125. Review.

8.

The clinical effectiveness and cost-effectiveness of peginterferon alfa and ribavirin for the treatment of chronic hepatitis C in children and young people: a systematic review and economic evaluation.

Hartwell D, Cooper K, Frampton GK, Baxter L, Loveman E.

Health Technol Assess. 2014 Oct;18(65):i-xxii, 1-202. doi: 10.3310/hta18650. Review.

9.

Spotlight on peginterferon-alpha-2a (40KD) in chronic hepatitis C.

Perry CM, Jarvis B.

BioDrugs. 2002;16(3):213-7. Review.

PMID:
12102649
10.
11.

Pharmacokinetics of peginterferons.

Zeuzem S, Welsch C, Herrmann E.

Semin Liver Dis. 2003;23 Suppl 1:23-8. Review.

PMID:
12934165
12.

Pharmacokinetics and pharmacodynamics of peginterferon and ribavirin: implications for clinical efficacy in the treatment of chronic hepatitis C.

Noureddin M, Ghany MG.

Gastroenterol Clin North Am. 2010 Sep;39(3):649-58. doi: 10.1016/j.gtc.2010.08.008. Review.

13.
14.

Spotlight on peginterferon-alpha-2a (40 kD) plus ribavirin in the management of chronic hepatitis C mono-infection.

Keam SJ, Cvetković RS.

BioDrugs. 2009;23(1):63-8. doi: 10.2165/00063030-200923010-00007. Review.

PMID:
19344193
15.

Pegylated interferon plus ribavirin for the treatment of chronic hepatitis C.

Baker DE.

Rev Gastroenterol Disord. 2003 Spring;3(2):93-109. Review.

PMID:
12776006
16.
17.

Treatment of chronic hepatitis C infection with peginterferons plus ribavirin.

Fried MW, Hadziyannis SJ.

Semin Liver Dis. 2004;24 Suppl 2:47-54. Review.

PMID:
15346246
18.

Pegylated interferons for the treatment of chronic hepatitis C infection.

Luxon BA, Grace M, Brassard D, Bordens R.

Clin Ther. 2002 Sep;24(9):1363-83. Review.

PMID:
12380630
19.

Peginterferon alfa-2a is superior to peginterferon alfa-2b in the treatment of naïve patients with hepatitis C virus infection: meta-analysis of randomized controlled trials.

Singal AK, Jampana SC, Anand BS.

Dig Dis Sci. 2011 Aug;56(8):2221-6. doi: 10.1007/s10620-011-1765-0. Epub 2011 Jun 4. Review.

PMID:
21643737
20.

[Side-effects of pegylated interferon plus ribavirin therapy with or without protease inhibitor direct acting antiviral agents during treatment of chronic hepatitis C virus infection].

Hunyady B, Kovács B, Battyáni Z.

Orv Hetil. 2011 Dec 11;152(50):1997-2009. doi: 10.1556/OH.2011.29266. Review. Hungarian.

PMID:
22112373

Supplemental Content

Support Center